S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
"Prepare for Five Years of Famine" (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
"Prepare for Five Years of Famine" (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
"Prepare for Five Years of Famine" (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
"Prepare for Five Years of Famine" (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
"Prepare for Five Years of Famine" (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
"Prepare for Five Years of Famine" (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
"Prepare for Five Years of Famine" (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
"Prepare for Five Years of Famine" (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:SYNH

Syneos Health - SYNH Stock Forecast, Price & News

$68.88
-0.58 (-0.84%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$68.46
$69.46
50-Day Range
$63.06
$79.14
52-Week Range
$62.28
$104.18
Volume
379,043 shs
Average Volume
771,714 shs
Market Capitalization
$7.07 billion
P/E Ratio
25.89
Dividend Yield
N/A
Price Target
$84.67

Syneos Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
22.9% Upside
$84.67 Price Target
Short Interest
Healthy
1.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.00
Upright™ Environmental Score
News Sentiment
-0.20mentions of Syneos Health in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
6.17%
From $4.54 to $4.82 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

264th out of 1,135 stocks

Commercial Physical Research Industry

6th out of 17 stocks

SYNH stock logo

About Syneos Health (NASDAQ:SYNH) Stock

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on SYNH shares. Robert W. Baird reduced their target price on shares of Syneos Health to $89.00 in a report on Tuesday, August 9th. Jefferies Financial Group lowered shares of Syneos Health from a "buy" rating to a "hold" rating and reduced their price objective for the company from $101.00 to $75.00 in a research note on Monday, April 25th. Guggenheim assumed coverage on shares of Syneos Health in a research note on Monday, May 23rd. They issued a "buy" rating and a $81.00 price objective on the stock. Barclays reduced their price objective on shares of Syneos Health from $90.00 to $80.00 in a research note on Wednesday, August 3rd. Finally, Citigroup reduced their price objective on shares of Syneos Health from $80.00 to $70.00 in a research note on Wednesday, August 3rd. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $84.67.

Syneos Health Stock Performance

SYNH opened at $68.88 on Friday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.86. The company's fifty day moving average price is $71.04 and its two-hundred day moving average price is $75.92. Syneos Health has a 1-year low of $62.28 and a 1-year high of $104.18. The company has a market cap of $7.07 billion, a price-to-earnings ratio of 25.89 and a beta of 1.68.

Syneos Health (NASDAQ:SYNH - Get Rating) last announced its earnings results on Tuesday, August 2nd. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.08 by $0.17. Syneos Health had a net margin of 5.13% and a return on equity of 14.04%. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.39 billion. During the same quarter in the prior year, the company posted $0.86 earnings per share. The firm's revenue for the quarter was up 6.0% on a year-over-year basis. On average, analysts expect that Syneos Health will post 4.54 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Michelle Keefe sold 8,333 shares of the firm's stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $72.81, for a total value of $606,725.73. Following the sale, the chief executive officer now directly owns 71,266 shares of the company's stock, valued at $5,188,877.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Syneos Health news, CEO Michelle Keefe sold 8,333 shares of Syneos Health stock in a transaction that occurred on Monday, July 18th. The shares were sold at an average price of $72.81, for a total transaction of $606,725.73. Following the transaction, the chief executive officer now directly owns 71,266 shares of the company's stock, valued at $5,188,877.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jonathan Olefson sold 2,215 shares of Syneos Health stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $75.00, for a total transaction of $166,125.00. Following the completion of the transaction, the general counsel now directly owns 25,292 shares in the company, valued at $1,896,900. The disclosure for this sale can be found here. Insiders sold 22,403 shares of company stock worth $1,646,313 over the last quarter. 0.34% of the stock is currently owned by company insiders.

Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

SYNH Stock News Headlines

Analysts Set Syneos Health, Inc. (NASDAQ:SYNH) PT at $84.67
The Day of Financial Reckoning Is Near
The cycles that accurately warned of the Great Depression and every major investment event since … are now warning that the most severe geopolitical earthquake of this century has just begun. This crisis is so urgent that Weiss Ratings cycles expert Sean Brodrick and I held an emergency summit to prepare investors for the fallout.
Syneos Health (NASDAQ:SYNH) Downgraded by William Blair
The Day of Financial Reckoning Is Near
The cycles that accurately warned of the Great Depression and every major investment event since … are now warning that the most severe geopolitical earthquake of this century has just begun. This crisis is so urgent that Weiss Ratings cycles expert Sean Brodrick and I held an emergency summit to prepare investors for the fallout.
Syneos Health (NASDAQ:SYNH) Price Target Cut to $70.00
Update: SYNH and GLDD, August 2
Syneos Health Reports Second Quarter 2022 Results
Syneos Health (SYNH) Beats Q2 Earnings Estimates
Michelle Keefe Joins Tandym Group as Board Member
See More Headlines
Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

SYNH Company Calendar

Last Earnings
8/02/2022
Today
8/14/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYNH
Employees
28,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$84.67
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+22.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$234.83 million
Pretax Margin
6.91%

Debt

Sales & Book Value

Annual Sales
$5.21 billion
Cash Flow
$6.29 per share
Book Value
$32.43 per share

Miscellaneous

Free Float
102,304,000
Market Cap
$7.07 billion
Optionable
Optionable
Beta
1.68














SYNH Stock - Frequently Asked Questions

Should I buy or sell Syneos Health stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SYNH shares.
View SYNH analyst ratings
or view top-rated stocks.

What is Syneos Health's stock price forecast for 2022?

9 brokers have issued twelve-month price objectives for Syneos Health's stock. Their SYNH share price forecasts range from $70.00 to $105.00. On average, they expect the company's stock price to reach $84.67 in the next twelve months. This suggests a possible upside of 22.9% from the stock's current price.
View analysts price targets for SYNH
or view top-rated stocks among Wall Street analysts.

How have SYNH shares performed in 2022?

Syneos Health's stock was trading at $102.68 at the beginning of 2022. Since then, SYNH stock has decreased by 32.9% and is now trading at $68.88.
View the best growth stocks for 2022 here
.

When is Syneos Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our SYNH earnings forecast
.

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) posted its quarterly earnings results on Tuesday, August, 2nd. The company reported $1.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.17. The firm earned $1.36 billion during the quarter, compared to analyst estimates of $1.39 billion. Syneos Health had a trailing twelve-month return on equity of 14.04% and a net margin of 5.13%. Syneos Health's quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.86 EPS.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of $4.97-$5.11 for the period, compared to the consensus earnings per share estimate of $5.11. The company issued revenue guidance of $5.44 billion-$5.54 billion, compared to the consensus revenue estimate of $5.66 billion.

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Block (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by many different institutional and retail investors. Top institutional investors include Clearbridge Investments LLC (4.02%), FMR LLC (3.83%), Massachusetts Financial Services Co. MA (3.05%), Cooke & Bieler LP (2.77%), Mackenzie Financial Corp (2.20%) and JPMorgan Chase & Co. (2.12%). Insiders that own company stock include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, John M Dineen, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Matthew E Monaghan, Michael Lee Brooks, Michelle Keefe, Paul Colvin, Robert Parks, Thomas H Lee Advisors, Llc and Tom Allen.
View institutional ownership trends
.

How do I buy shares of Syneos Health?

Shares of SYNH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $68.88.

How much money does Syneos Health make?

Syneos Health (NASDAQ:SYNH) has a market capitalization of $7.07 billion and generates $5.21 billion in revenue each year. The company earns $234.83 million in net income (profit) each year or $2.66 on an earnings per share basis.

How many employees does Syneos Health have?

The company employs 28,000 workers across the globe.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The official website for the company is www.syneoshealth.com. The company can be reached via phone at (919) 876-9300, via email at investor.relations@syneoshealth.com, or via fax at 919-876-9360.

This page (NASDAQ:SYNH) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.